RE:RE:OversightCAinPlap wrote: On the glass half full side, the delays have allowed us to identify the misstakes made and correct them. It would have really sucked if we had been treating patients in US and had treated half the expected participants before they discovered the deficiencies in the process. Dodged a bullet is right whoever said that. Also agree we need to add another year to our timeline. Hurry up and wait some more.
Is the undertreatment a software issue? Will we need to spend more time and money "fixing" this? NR sounds like they know how to do properly when things get going again but am disappointed they seem to be making avoidable misstakes. Did we just get lucky with patient 5 and 6 from Phase 1?
Problem is, as the old saying goes, excuses are for losers.